This study is looking at whether giving a medicine called Poractant Alfa (Curosurf) to very premature babies right after birth can help prevent breathing problems. This medicine is given using a special, minimally invasive (less invasive) method. The study wants to see if giving Poractant Alfa early works better than giving it later if the baby starts to have breathing difficulties. We are looking for 200 premature babies, born before 30 weeks of pregnancy, whose parents have given consent before birth. The main goal is to see how many babies need a breathing tube (endotracheal intubation) within the first 7 days. Babies with birth defects or other reasons for breathing problems cannot join.

Study design

This is a multicenter, randomized study, meaning babies will be assigned by chance to receive Poractant Alfa either right away or later if needed. The study plans to include 200 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The main outcome of the study is measured at 7 days after birth.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.